<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02871648</url>
  </required_header>
  <id_info>
    <org_study_id>2015P001664</org_study_id>
    <nct_id>NCT02871648</nct_id>
  </id_info>
  <brief_title>The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production</brief_title>
  <official_title>The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research protocol is to determine if the same effects are observed in
      vivo in humans using a similar approach. Demonstrating that mineralocorticoid acts on zona
      glomerulosa cells to regulate aldosterone production in a short feedback loop would provide
      important insight into hormone regulation, and explain variability in pathophysiologic states
      such as hypertension and cardiovascular diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to provide additional evidence indicating the presence of functional and in order to
      provide additional evidence indicating the presence of functional mineralocorticoid receptors
      (MR) on zona glomerulosa (ZG) cells, the investigators propose the following protocol in
      healthy volunteers. The investigators will evaluate aldosterone and cortisol production in
      response to an angiotensin II infusion after three separate test conditions: 1) placebo, 2)
      following a single dose of fludrocortisone, and 3) following a single dose of eplerenone (a
      MR antagonist).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum aldosterone after angiotensin II infusion</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum aldosterone after cosyntropin infusion</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cortisol after angiotensin II infusion</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cortisol after cosyntropin infusion</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urine aldosterone</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 hour urine aldosterone</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo prepared by Investigational Drug Services at Brigham and Women's Hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fludrocortisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 0.1 mg of fludrocortisone (Florinef) on one of three study days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epleronone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 100 mg of epleronone on one of three study days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludrocortisone</intervention_name>
    <description>Fludrocortisone 0.1 mg</description>
    <arm_group_label>Fludrocortisone</arm_group_label>
    <other_name>Florinef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <description>Epleronone 100 mg</description>
    <arm_group_label>Epleronone</arm_group_label>
    <other_name>Inspra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be healthy, with no prior history of hypertension, no family history
             of hypertension, diabetes, stroke or cardiac disease in first-degree relatives before
             the age of 70 years and have an average (two measurements) blood pressure of &lt;130/89
             mm Hg and &gt;100/50 mmHg at the screening visit.

          -  All subjects will have body mass index 19-25 kg/m2.

          -  Subjects must have normal laboratory values for: Complete blood count; serum
             creatinine, sodium, potassium, glucose, liver enzymes; urinalysis; negative urine HCG
             in women; normal ECG

        Exclusion Criteria:

          -  Alcohol intake &gt;12oz per week, as well as tobacco or recreational drug use.

          -  Any subject with a history of coronary disease, diabetes, hypertension, stroke, kidney
             disease, or illness requiring overnight hospitalization in the past 6 months will be
             excluded from the study.

          -  Subjects taking any prescription medications (with the exception of birth control
             pills) or herbal medications will be excluded.

          -  Because of the unknown risk of infused angiotensin II in pregnancy, women who are
             pregnant will be excluded from study and all women will be screened for pregnancy by
             quantitative serum hCG measurement on the day of each CCI admission.

          -  Women currently breastfeeding will also be excluded from the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan S Williams, MD, MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cara Ludwick</last_name>
    <phone>617-278-0305</phone>
    <email>cludwick1@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathan S Williams, MD, MMSc</last_name>
    <phone>617-278-0882</phone>
    <email>jwilliams5@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jonathan S Williams, MD, MMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gordon Williams, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tina Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Braley LM, Williams GH. Rat adrenal cell sensitivity to angiotensin II, alpha-1-24-ACTH, and potassium: a comparative study. Am J Physiol. 1977 Nov;233(5):E402-6.</citation>
    <PMID>200147</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2016</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Gordon H. Williams, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Healthy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Fludrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

